Roche

Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated non-inferiority in relapse control and superiority over fingolimod in suppressing brain lesions1 Safety in children and adolescents was aligned with the established safety profile of Ocrevus across more than 525,000 adult patients globally1 Basel, 18 September 2026 - Roche (SIX: RO,...

Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment Data reinforce the potential of this Lunsumio-based regimen to improve clinical outcomes, while offering a tolerable safety profile, simple dosing schedule and outpatient administration Data will be submitted to health...

The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development It will expand Roche’s and Genentech’s presence in Boston, reflecting a long-term commitment to one of the world’s leading life sciences hubs This is part of Roche and Genentech’s USD 50 billion investment in US manufacturing and R&D, building on recent investments and...

Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1 The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink’s proprietary TMALIN® platform, designed to maximise antitumour activity while minimising off-target toxicity2,3 Roche...

If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) Filing acceptance is based on the Phase III METEOROID study showing that Enspryng reduced the risk of relapses by 68%1 MOGAD is a rare disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord or brain2,3 Basel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the...

The Roche Investor Relations team would like to invite you to the Roche Pharma Day that will take place in London on Monday, 28 September 2026, starting at 09:00 BST and will finish at 14:30 BST with a reception.

The SALWEEN study showed significant improvements in vision and retinal health1 More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions1,2 By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing treatment burden1 Vabysmo was well tolerated with a consistent long-term safety profile1 Basel, 28 August 2026 - Roche (SIX: RO, ROP;...

First and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings The test delivers consistency across clinical settings by using the same validated cutoffs in primary and specialty care Designed for broad implementation across Roche's installed base of more than 4,500 cobas laboratory instruments in the U.S. supporting access through existing laboratory infrastructure Basel, August 24, 2026...

New facility in Hillsboro, Oregon for the assembly of injectable medicines and delivery devices will further advance end-to-end U.S. drug manufacturing capabilities. Approximately $750 million investment will double the size of the existing facility and is expected to create an additional 250 specialised manufacturing jobs. Flexible manufacturing capacity will support advanced drug delivery devices that can provide patients with more convenient ways to receive treatment.

The Roche Investor Relations team would like to invite you to the Roche Pharma Day that will take place in London on Monday, 28 September 2026, starting at 09:00 BST and will finish at 14:30 BST with a reception.